Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.

When Josef von Rickenbach created Parexel, not only did he create a company, he also helped invent an industry. Now, 35 years later, the Swiss native has stepped aside from CEO to chairman, likening the experience to sending your child to college; painful but ultimately necessary.

Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.

The wave of merger and acquisitions that has washed through the contract research organization sector this year is set to continue as the pharmaceutical industry increasingly turns to outsourcing for its clinical needs.